Document:

Form of Convertible Promissory Note

 Exhibit 4.10 

FORM OF CONVERTIBLE PROMISSORY NOTE 

THIS NOTE AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED BY ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER
THE SECURITIES ACT, OR (B) THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT IS AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE WITH ALL
APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS. 
 BG MEDICINE, INC. 

CONVERTIBLE PROMISSORY NOTE 
  

			
	Note-[    ]	 	
	US$ [            ]	 	March 30, 2010            

BG Medicine, Inc. a corporation duly formed under the laws of the State of Delaware, (the “Company”), for value
received, hereby promises to pay to [Name] or registered assigns (the “Note Holder”) the principal sum of $[            ], together with interest, in the
manner provided herein. This Convertible Promissory Note (this “Note”) is one of a series of notes (collectively, the “Notes”) issued pursuant to that certain Securities Purchase Agreement dated March 30, 2010
between the Company and the Purchasers (as defined therein) (the “Purchase Agreement”), and is entitled to the benefits of the Purchase Agreement. The terms of the Notes (including this Note) are and will be identical except as to
the name of the holder thereof, the original principal amount thereof and the date of issuance thereof. Except as to those terms otherwise defined in this Note, all capitalized terms used in this Note shall have the respective meanings ascribed to
them in the Purchase Agreement. 
 1. Payments. 

(a) Subject to Sections 6, 7 and 8 hereof, unless earlier converted or repaid as provided in Section 3 herein,
all amounts outstanding and unpaid under this Note shall be due and payable on the earliest of: (a) DEMAND by the Purchasers holding Notes with at least
66 2/3% of the aggregate principal amounts then
outstanding under all of the Notes, (b) acceleration due to the occurrence of an Event of Default, (c) the consummation of a Liquidation Event, or (d) 364 days following the date of issuance of this Note (the earliest to occur shall
be the “Due Date”). 
 (b) Subject to Section 8 hereof, and notwithstanding anything to the
contrary contained elsewhere herein (other than in Section 8) or in any of the Purchase Documents, the Company may, at its option, at any time and from time to time, prepay all or any part of the principal balance of this Note, without penalty
or premium; provided, however, that the Company shall make no payment with respect to this Note, whether in respect of principal, interest or any other amount 

 

 1 

 
owing hereunder, (i) without the prior written approval of the Purchasers holding Notes with at least
66 2/3% of the aggregate principal amounts then
outstanding under all of the Notes, and (ii) unless at the same time the Company makes a similar payment with respect to each of the Notes then outstanding in a pro rata amount based on the aggregate amounts then owing hereunder and thereunder,
except if any of the Note Holders waives such pro rata payment requirement. 
 2. Interest. 

Interest on the unpaid principal amount shall be deemed to have accrued beginning on the date of issuance of this Note at a rate equal to
twelve percent (12%) per annum, computed on the basis of the actual number of days elapsed and a year of 365 days from the date of this Note until the principal amount and all interest accrued thereon are paid (or converted, as provided in
Section 3 hereof). Subject to Section 3, interest shall not be due and payable until the Due Date. Notwithstanding any other provision of this Note, the Note Holder hereof does not intend to charge and the Company shall not be required to
pay any interest or other fees or charges in excess of the maximum interest permitted by applicable law, and any payments in excess of such maximum shall be refunded to the Company or credited to reduce principal hereunder. 

3. Conversion and Registration Rights. 

(a) Automatic Conversion in Connection with a Qualified Financing. The unpaid principal amount of this Note together with any
interest accrued but unpaid thereon, shall automatically be converted into shares of New Stock issued and sold at the closing of a Qualified Financing that occurs on or prior to the Due Date (it being understood that if such Qualified Financing
consists of more than one type of security, the holder of this Note shall be entitled to receive all of such securities upon such conversion). Upon the conversion of the Note pursuant to this Section 3(a), the holder of this Note shall be
entitled to receive a number of shares of the Company’s New Stock to be issued upon such conversion equal to the quotient obtained by dividing (i) the unpaid principal amount of this Note plus interest accrued but unpaid thereon, by
(ii) the New Stock Price. The issuance of the shares of New Stock upon such conversion shall be upon the terms and subject to the conditions applicable to the Qualified Financing. Upon such conversion, the Note Holder will execute such
agreements as may be entered into by purchasers of shares of New Stock in the Qualified Financing generally, if any. If the Qualified Financing is the Company’s Initial Public Offering, the New Stock shall be shares of the Company’s Common
Stock and the New Stock Price shall be the initial public offering price to the public in the Initial Public Offering. 
 (b)
Registration Rights. The holder of the securities issued upon conversion of this Note shall be entitled to the registration rights provided in the Fourth Amended and Restated Investor Rights Agreement, as amended from time to time, upon
becoming a party to such agreement (if not already a party), with such securities being deemed “Registrable Securities” thereunder. 

4. Mechanics of Conversion. 

(a) No fractional shares will be issued upon conversion of this Note. In lieu of any fractional share to which the Note Holder would
otherwise be entitled, the Company will pay to the Note Holder in cash any amount that would otherwise be converted into such fractional share. 
  

 2 

 (b) In the event that this Note is converted into New Stock pursuant to Section 3(a),
the Note Holder shall surrender this Note, duly endorsed, to the Company at the closing of the Qualified Financing and the Note shall thereupon be canceled. As soon as practicable following surrender of this Note and at its expense, the Company will
issue and deliver to the Note Holder, a certificate or certificates representing the number of shares of New Stock to which the Note Holder is entitled upon such conversion, together with a check payable to the Note Holder for any cash amounts
payable pursuant to Section 4(a). 
 5. Liquidation Event. 

In the event that, prior to the Due Date or conversion of the Note in accordance with Section 3, a written proposal from a third
party is made with respect to a Liquidation Event, the Company shall notify the Note Holder of such proposal promptly following receipt of such proposal and the Note Holder shall be entitled to receive, upon consummation of such Liquidation Event,
an amount equal to the sum of (i) five (5) times the then outstanding principal amount under this Note and (ii) one (1) times the then current accrued but unpaid interest under this Note. 

6. Subsequent Tranche Default. 

In the event that, at any time while this Note is outstanding, the Company conducts a Subsequent Tranche Closing under the Purchase
Agreement and the Note Holder defaults on its obligation to purchase an amount of additional Notes and Warrants in the Subsequent Tranche Closing at least equal to (i) the defaulting Note Holder’s allocation percentage of the Aggregate
Bridge Amount, as set forth opposite the name of such Note Holder on Schedule A attached to the Purchase Agreement under the caption “Allocation Percentage,” multiplied by (ii) the aggregate amount of such Subsequent Tranche, then all
of this Note Holder’s rights with respect to this Note shall terminate on the Subsequent Tranche Closing; and whether or not this Note has been surrendered for cancellation, the Company will be forever released from all of its obligations and
liabilities under this Note, including, but not limited to, all obligations to pay the outstanding principal and any accrued interest on this Note, and this Note will terminate and become null and void. For purposes of determining the number of
Notes and Warrants purchased by a Note Holder at a Subsequent Tranche Closing, all Notes and Warrants purchased by Affiliates of such Note Holder at the Subsequent Tranche Closing shall be aggregated with the Notes and Warrants purchased by such
Note Holder (provided that no securities shall be attributed to more than one entity or person within any such group of affiliated entities or persons). For the avoidance of doubt, Note Holders may allocate and transfer their Notes and Warrants
among their Affiliates, in their sole discretion, and all Notes and Warrants being purchased by a Note Holder’s Affiliates shall be attributed to such Note Holder or group of such Note Holder’s Affiliates, as applicable, for purposes of
determining such Note Holder’s or such Note Holder’s Affiliates’ commitment to purchase its Allocation Percentage of the Aggregate Bridge Amount. 
  

 3 

 7. Termination of Rights. 

Upon (i) the occurrence of a Subsequent Tranche Default by the Note Holder, (ii) conversion of this Note in accordance with
Section 3 hereof, (iii) repayment of this Note in accordance with Section 1 hereof, or (iv) repayment of this Note in connection with a Liquidation Event in accordance with Section 5 hereof, all rights with respect to this
Note shall terminate, whether or not the Note has been surrendered for cancellation, and the Company will be forever released from all of its obligations and liabilities under this Note, except its obligations pursuant to Section 3(b) in the
event of conversion of this Note in accordance with clause (ii) of this Section 7. 
 8. Subordination to Senior
Debt. 
 Note Holder agrees by accepting this Note that the payment of all principal, interest and other sums at any time now
or hereafter owing from the Company to Note Holder under or in connection with this Note (the “Subordinated Debt”) shall be junior and subordinate to the prior indefeasible payment in full of, and performance of all obligations in
respect of, all Senior Debt (as defined in the Purchase Agreement) in accordance with the terms and conditions of this Section 8. Until the date that is 91 days after the Senior Debt has been paid in full and the holders of the Senior Debt have
no obligation to make loans or otherwise extend credit to the Company, Note Holder by accepting this Note agrees that it will not (x) take any action or initiate any proceedings, judicial or otherwise, to enforce Note Holder’s rights or
remedies with respect to any indebtedness under this Note (other than the conversion of the indebtedness under this Note into New Stock pursuant to Section 3 hereof, so long as no cash is paid by the Company to the Note Holder in connection
with such conversion other than with respect to fractional shares pursuant to Section 4(a) hereof) or (y) demand or receive any payment of Subordinated Debt. Note Holder agrees that it shall promptly deliver to the holders of the Senior
Debt in the form received for application to the Senior Debt any payment, distribution, security or proceeds received by Note Holder with respect to Subordinated Debt that is made in contravention of this Section 8. In the event of any
insolvency, bankruptcy or receivership case or proceeding, or any dissolution, winding up, liquidation, reorganization or other similar proceeding, relative to the Company, its property or its operations (whether voluntary or involuntary and whether
in bankruptcy, insolvency or receivership proceedings or otherwise) or upon an assignment for the benefit of creditors, then all Senior Debt shall first be paid in full in cash or cash equivalents before Note Holder shall be entitled to receive or
retain any payment or distribution of assets with respect to this Note or the Subordinated Debt. By accepting this Note, Note Holder acknowledges and agrees that the holders of Senior Debt are intended to be third party beneficiaries of the
provisions of this Section 8 and are entitled to rely on these provisions and to enforce these provisions as if they were a direct party to this Note. 

The provisions of this Section 8 shall not prohibit the Company or the Note Holders from converting any Subordinated Debt evidenced
by this Note into shares of New Stock pursuant to Section 3 hereof, so long as no cash is paid by the Company to the Note Holder in connection with such conversion other than with respect to fractional shares pursuant to Section 4(a)
hereof. 
  

 4 

 9. Events of Default. 

Subject to Section 8 hereof, in the case an Event of Default shall occur, the entire unpaid principal of this Note shall become due
and payable in the manner and with the effect provided in the Purchase Agreement and this Note. 
 10. Transfer; Successors
and Assigns. 
 The Note Holder may not sell, assign, pledge, dispose of or otherwise transfer this Note or any interest
herein without the prior written consent of the Company; provided, however, a Note Holder that is partnership, corporation, trust, joint venture, unincorporated organization or other entity may transfer this Note to an Affiliate without the prior
written consent of the Company. Subject to the preceding sentence, this Note may be transferred only upon surrender of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in
form satisfactory to the Company. Thereupon, a new note for the same principal amount and interest will be issued to, and registered in the name, of, the transferee. Interest and principal are payable only to the registered holder of this Note. The
terms and conditions of this Note shall inure to the benefit of and binding upon the respective successors and assigns of the parties. Any assignee of this Note shall be bound by the terms and conditions of Section 8 hereof. 

11. Governing Law. 

This Note and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed
and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law and choice of law that would cause the laws of any other jurisdiction to apply. 

12. Notices. 

All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to
the party to be notified; (b) when sent by confirmed telecopy or facsimile if sent during normal business hours of the recipient, if not, then on the next business day; (c) five days after having been sent by registered or certified mail,
return receipt requested, postage prepaid; or (d) the next business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to
(i) the Company at the address as set forth on the signature page hereof and (ii) the Note Holder at the address set forth on the signature page hereof or at such other address as the Company or the Note Holder may designate by ten
days’ advance written notice to the other party hereto. 
 13. Amendments and Waivers. 

This Note may be amended or modified, and any provision hereof may be waived (either generally or in a particular
instance and either retroactively or prospectively) with the written consent of the Company and by the Purchasers holding Notes with at least
66 2/3% of the aggregate principal amounts then
outstanding under all of the Notes; provided, that this Note may not be amended or modified and no provision hereof may be waived in a manner different from any other Note without the consent of the Note Holder hereof. No waivers of any term,
condition or provision of this Note, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 

 

 5 

 14. Headings. 

The headings in this Note are for purposes of reference only, and shall not limit or otherwise affect the meaning hereof. 

15. Rights Reserved. 

No provisions of this Note and no right or option granted or conferred herein shall in any way limit, affect or abridge the exercise by
the Company of any of its corporate rights or powers, including without limitation, its corporate right and power to issue securities, recapitalize, amend its Certificate of Incorporation, reorganize, consolidate or merge with or into another
corporation, or transfer or encumber all or any part of its property or assets. 
 16. New Note. 

Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Note, the Company
will issue a new promissory note, of like tenor and amount and dated the original date of this Note, in lieu of such lost, stolen, destroyed or mutilated Note, and in such event the Note Holder thereof agrees to indemnify and hold harmless the
Company in respect of any such lost, stolen, destroyed or mutilated Note. 
 17. Collection. 

The Company agrees to pay all of the Note Holder’s reasonable costs in collecting and enforcing this Note, including all
attorney’s fees and disbursements, subject to any limitation imposed by law. All payments received by the Holder hereunder will be applied first to costs of collection, if any, then to interest and the balance to principal. 

18. Waiver by Company. 

The Company hereby expressly waives presentment, demand, and protest, notice of demand, dishonor and nonpayment of this Note, and all
other notices or demands of any kind in connection with the delivery, acceptance, performance, default or enforcement hereof, and hereby consents to any delays, extensions of time, renewals, waivers or modifications that may be granted or consented
to by the Note Holder hereof with respect to the time of payment or any other provision hereof. 
  

 6 

 IN WITNESS WHEREOF, the Company has caused this Note to be duly executed and delivered.

  

			
	BG MEDICINE, INC.
		
	By:	 	  

	Name:	 	Pieter Muntendam, M.D.
	Title:	 	President & Chief Executive Officer
	Address:	 	 610 N Lincoln Street

Waltham, MA 02451

  

 7 

 Schedule of Note Holders 

AGTC Advisors Fund, L.P. 
 Applied Genomic
Technology Capital Fund, L. P. 
 General Electric Pension Trust 

Gilde Europe Food & Agribusiness Fund, B.V. 

Humana Inc. 
 Legg Mason Special Investment
Trust, Inc. 
 NewcoGen—Élan LLC 

NewcoGen—Long Reign Holding LLC 

NewcoGen—PE LLC 
 NewcoGen Equity Investors
LLC 
 NewcoGen Group LLC 
 SMALLCAP
World Fund, Inc. (nominee name: Clipperbay & Co. HG 22) 
 ST NewcoGen LLC 

Stelios Papadopoulos 
  

 8First Loan Modification Agreement

 Exhibit 10.3.1 

FIRST LOAN MODIFICATION AGREEMENT 

This First Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of March 28, 2008, by and
between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at One Newton Executive Park, Suite 200, 2221 Washington
Street, Newton, Massachusetts 02462 (“Bank”) and BG MEDICINE, INC., a Delaware corporation with its chief executive office located at 610 Lincoln Street, Waltham, Massachusetts 02451. 

1. DESCRIPTION OF EXISTING INDEBTEDNESS AND OBLIGATIONS. Among other indebtedness and obligations which may be owing by Borrower to Bank, Borrower
is indebted to Bank pursuant to a loan arrangement dated as of November 9, 2007, evidenced by, among other documents, a certain Loan and Security Agreement dated as of November 9, 2007, between Borrower and Bank (as amended, the “Loan
Agreement”). Capitalized terms used but not otherwise defined herein shall have the same meaning as in the Loan Agreement. 
 2.
DESCRIPTION OF COLLATERAL. Repayment of the Obligations is secured by (a) the Collateral as described in the Loan Agreement and (b) the Intellectual Property Collateral as described in a certain Intellectual Property Security
Agreement dated as of November 9, 2007 between Borrower and Bank (the “IP Security Agreement”) (together with any other collateral security granted to Bank, the “Security Documents”). 

Hereinafter, the Security Documents, together with all other documents evidencing or securing the Obligations shall be referred to as the “Existing
Loan Documents”. 
  

	3.	DESCRIPTION OF CHANGE IN TERMS. 

  

	 	A.	Modifications to Loan Agreement. 

  

	 	1.	The Loan Agreement shall by amended by inserting the following text to appear at the end of Section 2.1.1(b): 

“Notwithstanding the foregoing, if the Financing Event occurs on or before June 30, 2008, at Borrower’s election, which
shall be exercised by written notice to Bank on or before June 30, 2008, the Bridge Loan Maturity Date shall be extended and the aggregate outstanding Obligations under the Bridge Loan shall repaid as follows: 

(i) Commencing on July 1, 2008, and continuing on the Payment Date of each month thereafter, the Bridge Loan shall
be repaid in (i) thirty (30) equal monthly installments of principal, plus (ii) monthly payments of accrued interest at the rate set forth in Section 2.2(a). All unpaid principal and accrued interest is due on the Bridge Loan
Maturity Date.” 
  

	 	2.	The Loan Agreement shall by amended by inserting the following new provisions to appear as subsections (c) and (d) in Section 2.1.1:

 (c) Mandatory Prepayment Upon an Acceleration. If the Bridge Loan Advances are accelerated following the
occurrence of an Event of Default, Borrower shall immediately pay to Bank an amount equal to the sum of (i) all outstanding principal plus accrued and unpaid interest, (ii) the Final Payment (if the Bridge Loan Maturity Date is extended
pursuant to Section 2.1.1(b)(i)), and (iii) all other sums, if any, that shall have become due and payable, including interest at the Default Rate with respect to any past due amounts. 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (d) Permitted Prepayment of Bridge Loan Advances. So long as no Event of Default has
occurred and is continuing, Borrower shall have the option to prepay all, but not less than all, of the Bridge Loan Advances advanced by Bank under this Agreement, provided Borrower (i) delivers written notice to Bank of its election to prepay
the Bridge Loan Advances at least five (5) days prior to such prepayment, and (ii) pays, on the date of such prepayment (A) all outstanding principal plus accrued and unpaid interest, (B) the Final Payment (if the Bridge Loan
Maturity Date is extended pursuant to Section 2.1.1(b)(i)), and (C) all other sums, if any, that shall have become due and payable, including interest at the Default Rate with respect to any past due amounts.” 

 

	 	3.	The Loan Agreement shall be amended by inserting the following text to appear at the end of Section 2.3, entitled “Fees”: 

“(c) Final Payment. The Final Payment, when due hereunder.” 

 

	 	4.	The Loan Agreement shall by amended by deleting Section 6.2 thereof, entitled “Financial Statements, Reports, Certificates”: 

“6.2 Financial Statements, Reports, Certificates. Deliver to Bank: (i) as soon as available, but no later than thirty
(30) days after the last day of each month, a company prepared consolidated balance sheet and income statement covering Borrower’s consolidated operations during the period certified by a Responsible Officer and in a form acceptable to
Bank; (ii) within five (5) days of delivery, copies of all statements, reports and notices made available to Borrower’s security holders or to any holders of Subordinated Debt; (iii) in the event that Borrower becomes subject to
the reporting requirements under the Securities Exchange Act of 1934, as amended, within five (5) days of filing, all reports on Form 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission or a link thereto on Borrower’s or
another website on the Internet; (iv) a prompt report of any legal actions pending or threatened against Borrower or any of its Subsidiaries that could result in damages or costs to Borrower or any of its Subsidiaries of One Hundred Thousand
Dollars ($100,000) or more; (v) prompt notice of an event that materially and adversely affects the value of the intellectual property taken as a whole; and (vi) budgets, sales projections, operating plans and other financial information
reasonably requested by Bank.” 
 and inserting in lieu thereof the following: 

“6.2 Financial Statements, Reports, Certificates. Deliver to Bank: (i) as soon as available, but no later than thirty
(30) days after the last day of each month, a company prepared consolidated balance sheet and income statement covering Borrower’s consolidated operations during the period certified by a Responsible Officer and in a form acceptable to
Bank; (ii) as soon as available, but no later than one hundred eighty (180) days after the last day of Borrower’s fiscal year, audited consolidated financial statements prepared under GAAP, consistently applied, together with an
unqualified opinion on the financial statements from an independent certified public accounting firm acceptable to Bank in its reasonable discretion; (iii) within five (5) days of delivery, copies of all statements, reports and notices
made available to Borrower’s security 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

2 

 
holders or to any holders of Subordinated Debt; (iv) in the event that Borrower becomes subject to the reporting requirements under the Securities Exchange Act of 1934, as amended, within
five (5) days of filing, all reports on Form 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission or a link thereto on Borrower’s or another website on the Internet; (v) a prompt report of any legal actions pending or
threatened against Borrower or any of its Subsidiaries that could result in damages or costs to Borrower or any of its Subsidiaries of One Hundred Thousand Dollars ($100,000) or more; (vi) prompt notice of an event that materially and adversely
affects the value of the intellectual property taken as a whole; (vii) as soon as available, but no later than forty-five (45) days after the last day of Borrower’s fiscal year, Borrower’s Board-approved projections; and
(viii) budgets, sales projections, operating plans and other financial information reasonably requested by Bank.” 
  

	 	5.	The Loan Agreement shall be amended by inserting the following new definitions to appear alphabetically in Section 13.1 thereof: 

“2008 Effective Date” is March 28, 2008.” 

“Board” is Borrower’s board of directors.” 

“Equity Event” shall mean receipt of unrestricted net cash proceeds by the Borrower, after the 2008 Effective Date, from
the closing of an equity or debt round of financing with investors reasonably acceptable to the Bank, in the amount of at least Two Million Dollars ($2,000,000.00).” 

“Final Payment” is, if the Bridge Loan Maturity Date is extended pursuant to Section 2.1.1(b)(i), a payment (in
addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due on the earlier of (a) the Bridge Loan Maturity Date for such Bridge Loan Advance or (b) the acceleration of such Bridge Loan
Advance, equal to the amount for such Bridge Advance multiplied by the Final Payment Percentage.” 
 “Final Payment
Percentage” is, for each Bridge Loan Advance, one and one half of one percent (1.5%).” 
  

	 	6.	The Loan Agreement shall be amended by deleting the following definitions appearing in Section 13.1 thereof: 

“Bridge Loan Maturity Date” is, the sooner to occur of (a) five (5) days after the occurrence of the Financing
Event, (b) March 31, 2008, or (c) the Borrower’s initial public offering and sale of its Common Stock or other common voting equity securities pursuant to an effective registration statement under the Securities Act of 1933, as
amended.” 
 “Financing Event” shall mean the closing by the Borrower of a debt or equity financing after
the Effective Date.” 
 “Obligations” are Borrower’s obligation to pay when due any debts, principal,
interest, Bank Expenses and other amounts Borrower owes Bank now or later, in connection with this Agreement, the Loan Documents, or otherwise, including, without limitation, all obligations relating to letters of credit (including reimbursement
obligations for drawn 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

3 

 
and undrawn letters of credit), cash management services, and foreign exchange contracts, if any, and including interest accruing after Insolvency Proceedings begin and debts, liabilities, or
obligations of Borrower assigned to Bank, and the performance of Borrower’s duties under the Loan Documents.” 

“Second Draw Period” is the period of time commencing upon on February 1, 2008 through the earliest to occur of
(a) Bridge Loan Maturity Date, and (b) an Event of Default.” 
 and inserting in lieu thereof the following:

 “Bridge Loan Maturity Date” is June 30, 2008. Notwithstanding the foregoing, if (a) the Financing
Event has occurred, and (b) Borrower elects to extend the payment period pursuant to Section 2.1.1(b), the Bridge Loan Maturity Date shall be October 1, 2010.” 

“Financing Event” shall mean receipt of unrestricted net cash proceeds by the Borrower, after the Funding Date of the
Second Bridge Loan Advance but on or before June 30, 2008, from the closing of an equity round of financing with investors reasonably acceptable to the Lenders, in the amount of at least Fifteen Million Dollars ($15,000,000.00). 

“Obligations” are Borrower’s obligation to pay when due any debts, principal, interest, Final Payment, Bank
Expenses and other amounts Borrower owes Bank now or later, in connection with this Agreement, the Loan Documents, or otherwise, including, without limitation, all obligations relating to letters of credit (including reimbursement obligations for
drawn and undrawn letters of credit), cash management services, and foreign exchange contracts, if any, and including interest accruing after Insolvency Proceedings begin and debts, liabilities, or obligations of Borrower assigned to Bank, and the
performance of Borrower’s duties under the Loan Documents.” 
 “Second Draw Period” is the period of
time commencing upon on the Equity Event through the earliest to occur of (a) June 30, 2008, and (b) an Event of Default.” 

4. CONSENT TO BRIDGE FINANCING. Borrower is completing, on or about the date hereof, a bridge financing of up to approximately Two Million Dollars
($2,000,000.00) (the “Bridge Financing”), from and with certain of the Borrower’s investors, as attached hereto as Exhibit A (individually and collectively, the “Bridge Financing Investors”). Pursuant to
Sections 7.4 of the Loan Agreement, relative to Borrower’s incurring Indebtedness, the Bank hereby consents to the Bridge Financing and agrees that the Bridge Financing shall be considered Permitted Indebtedness and a Permitted Lien; provided,
however, that such consent by the Bank is expressly conditioned upon each Bridge Financing Investor executing and delivering to Bank a subordination agreement, on terms and conditions and in the form attached hereto as Exhibit B, on or
before the 2008 Effective Date. 
 5. FEES. A fully earned, non-refundable commitment fee of Fifteen Thousand Dollars ($15,000.00) is
earned as of the date hereof and shall be payable on the Funding Date of the Second Bridge Loan Advance. Borrower shall also reimburse Bank for all legal fees and expenses incurred in connection with this amendment to the Existing Loan Documents.

 6. RATIFICATION OF IP SECURITY AGREEMENT. Borrower hereby ratifies, confirms and reaffirms, all and singular, the terms and conditions
of the IP Security Agreement, and acknowledges, confirms and agrees that said IP Security Agreement contains an accurate and complete listing of all Intellectual Property Collateral as defined in said IP Security Agreement, except to the extent such
listing is updated by the information contained in Exhibit C and shall remain in full force and effect. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

4 

 7. RATIFICATION OF PERFECTION CERTIFICATE. Borrower hereby ratifies, confirms and reaffirms, all and
singular, the terms and disclosures contained in a certain Perfection Certificate dated as of November 9, 2007, between Borrower and Bank, and acknowledges, confirms and agrees the disclosures and information Borrower provided to Bank in the
Perfection Certificate have not changed, as of the date hereof, except to the extent such disclosure is updated by the information contained in Exhibit D attached hereto. 

8. CONSISTENT CHANGES. The Existing Loan Documents are hereby amended wherever necessary to reflect the changes described above. 

9. RATIFICATION OF LOAN DOCUMENTS. Borrower hereby ratifies, confirms, and reaffirms all terms and conditions of all security or other collateral
granted to the Bank, and confirms that the indebtedness secured thereby includes, without limitation, the Obligations. 
 10. NO DEFENSES OF
BORROWER. Borrower hereby acknowledges and agrees that Borrower has no offsets, defenses, claims, or counterclaims against Bank with respect to the Obligations, or otherwise, and that if Borrower now has, or ever did have, any offsets, defenses,
claims, or counterclaims against Bank, whether known or unknown, at law or in equity, all of them are hereby expressly WAIVED and Borrower hereby RELEASES Bank from any liability thereunder. 

11. CONTINUING VALIDITY. Borrower understands and agrees that in modifying the existing Obligations, Bank is relying upon Borrower’s
representations, warranties, and agreements, as set forth in the Existing Loan Documents. Except as expressly modified pursuant to this Loan Modification Agreement, the terms of the Existing Loan Documents remain unchanged and in full force and
effect. Bank’s agreement to modifications to the existing Obligations pursuant to this Loan Modification Agreement in no way shall obligate Bank to make any future modifications to the Obligations. Nothing in this Loan Modification Agreement
shall constitute a satisfaction of the Obligations. It is the intention of Bank and Borrower to retain as liable parties all makers of Existing Loan Documents, unless the party is expressly released by Bank in writing. No maker will be released by
virtue of this Loan Modification Agreement. 
 12. COUNTERSIGNATURE. This Loan Modification Agreement shall become effective only when it
shall have been executed by Borrower and Bank. 
 [The remainder of this page is intentionally left blank] 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

5 

 This Loan Modification Agreement is executed as a sealed instrument under the laws of the
Commonwealth of Massachusetts as of the date first written above. 
  

							
	 BORROWER
	  	 BANK:

		
	BG MEDICINE, INC.	  	SILICON VALLEY BANK
				
	By:	  	 /s/ Pieter Muntendam
	  	By:	  	 /s/ Clark Hayes

	Name:	  	Pieter Muntendam	  	Name:	  	Clark Hayes
	Title:	  	President	  	Title:	  	RM

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

6 

 EXHIBIT A 

Exhibit A 

SCHEDULE A 

List of Purchasers 
  

						
	 Purchasers
	  	Issuance
Date of Note	  	Principal
Amount of Note
	 Applied Genomic Technology

Capital Fund, L.P.

c/o Flagship Ventures
	  	March 26, 2008	  	$	729,910
			
	 AGTC Advisors Fund, L.P.

c/o Flagship Ventures
	  	March 26, 2008	  	$	44,120
			
	 NewcoGen Equity Investors LLC

c/o Flagship Ventures
	  	March 26, 2008	  	$	216,270
			
	 NewcoGen-Long Reign Holding LLC

c/o Flagship Ventures
	  	March 26, 2008	  	$	30,693
			
	 NewcoGen-PE LLC

c/o Flagship Ventures
	  	March 26, 2008	  	$	93,201
			
	 ST NewcoGen LLC

c/o Flagship Ventures
	  	March 26, 2008	  	$	30,606
		  		  	 	 
			
	 FLAGSHIP SUBTOTAL
	  		  	$	1,144,800
		  		  	 	 
			
	 Stelios Papadopoulos
	  	March 26, 2008	  	$	261,600
			
	 GILDE EUROPE FOOD & AGRIBUSINESS FUND B.V.
	  	March 26, 2008	  	$	593,600
		  		  	 	 
			
	 TOTAL
	  		  	$	2,000,000
		  		  	 	 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

7 

 EXHIBIT B 

SUBORDINATION AGREEMENT 

This Subordination Agreement is made as of March 28, 2008, by and between
            (“Creditor”), and SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara,
California 95054 and with a loan production office located at 2221 Washington Street, Suite 200, Newton, Massachusetts 02462 (“Bank”). 

Recitals 

BG MEDICINE, INC. (“Borrower”) has requested and/or obtained certain loans or other credit accommodations from Bank to
Borrower which are or may be from time to time secured by assets and property of Borrower. 
 Creditor has extended loans or
other credit accommodations to Borrower, and/or may extend loans or other credit accommodations to Borrower from time to time. 

In order to induce Bank to extend credit to Borrower and, at any time or from time to time, at Bank’s option, to make such further
loans, extensions of credit, or other accommodations to or for the account of Borrower, or to purchase or extend credit upon any instrument or writing in respect of which Borrower may be liable in any capacity, or to grant such renewals or extension
of any such loan, extension of credit, purchase, or other accommodation as Bank may deem advisable, Creditor is willing to subordinate: (i) all of Borrower’s indebtedness and obligations to Creditor, whether presently existing or arising
in the future (the “Subordinated Debt”) to all of Borrower’s indebtedness and obligations to Bank; and (ii) all of Creditor’s security interests, if any, to all of Bank’s security interests in the Borrower’s
property. 
 NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS: 

Creditor subordinates to Bank any security interest or lien that Creditor may have in any property of Borrower. Notwithstanding the
respective dates of attachment or perfection of the security interest of Creditor and the security interest of Bank, the security interest of Bank in the Collateral (the “Collateral”), as defined in a certain Loan and Security Agreement
between Borrower and Bank dated as of November 9, 2007, as amended by that certain First Loan Modification Agreement between Borrower and Bank dated of even date herewith, and as may be further amended from time to time (as amended and in
effect, the “Loan Agreement”), shall at all times be senior to the security interest of Creditor. 
 All Subordinated
Debt is subordinated in right of payment to all obligations of Borrower to Bank now existing or hereafter arising, together with all costs of collecting such obligations (including attorneys’ fees), including, without limitation, all interest
accruing after the commencement by or against Borrower of any bankruptcy, reorganization or similar proceeding, and all obligations under the Loan Agreement (the “Senior Debt”). 

Creditor will not demand or receive from Borrower (and Borrower will not pay to Creditor) all or any part of the Subordinated Debt, by
way of payment, prepayment, setoff, lawsuit or otherwise, nor will Creditor exercise any remedy with respect to the Collateral, nor will Creditor accelerate the Subordinated Debt, or commence, or cause to commence, prosecute or participate in any
administrative, legal or equitable action against Borrower, until such time as (i) the Senior Debt is fully paid in cash, (ii) Bank has no commitment or obligation to lend any further funds to Borrower, and (iii) all financing
agreements between Bank and Borrower are terminated. Nothing in the foregoing paragraph shall prohibit Creditor from converting all or any part of the Subordinated Debt into equity securities of Borrower. 

Creditor shall promptly deliver to Bank in the form received (except for endorsement or assignment by Creditor where required by Bank)
for application to the Senior Debt any payment, distribution, security or proceeds received by Creditor with respect to the Subordinated Debt other than in accordance with this Agreement. 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

1 

 In the event of Borrower’s insolvency, reorganization or any case or proceeding under
any bankruptcy or insolvency law or laws relating to the relief of debtors, these provisions shall remain in full force and effect, and Bank’s claims against Borrower and the estate of Borrower shall be paid in full before any payment is made
to Creditor. 
 Until the Senior Debt is fully paid in cash and Bank’s arrangements to lend any funds to Borrower has been
terminated, Creditor irrevocably appoints Bank as Creditor’s attorney-in-fact, and grants to Bank a power of attorney with full power of substitution, in the name of Creditor or in the name of Bank, for the use and benefit of Bank, without
notice to Creditor, to perform at Bank’s option the following acts in any bankruptcy, insolvency or similar proceeding involving Borrower: 

To file the appropriate claim or claims in respect of the Subordinated Debt on behalf of Creditor if Creditor does not do
so prior to 30 days before the expiration of the time to file claims in such proceeding and if Bank elects, in its sole discretion, to file such claim or claims; and 

To accept or reject any plan of reorganization or arrangement on behalf of Creditor and to otherwise vote Creditor’s
claims in respect of any Subordinated Debt in any manner that Bank deems appropriate for the enforcement of its rights hereunder. 

Creditor shall immediately affix a legend to the instruments evidencing the Subordinated Debt stating that the instruments are subject to
the terms of this Agreement. By the execution of this Agreement, Creditor hereby authorizes Bank to amend any financing statements filed by Creditor against Borrower as follows: “In accordance with a certain Subordination Agreement by and among
the Secured Party, the Debtor and Silicon Valley Bank, the Secured Party has subordinated any security interest or lien that Secured Party may have in any property of the Debtor to the security interest of Silicon Valley Bank in all assets of the
Debtor, notwithstanding the respective dates of attachment or perfection of the security interest of the Secured Party and Silicon Valley Bank.” 

No amendment of the documents evidencing or relating to the Subordinated Debt shall directly or indirectly modify the provisions of this
Agreement in any manner which might terminate or impair the subordination of the Subordinated Debt or the subordination of the security interest or lien that Creditor may have in any property of Borrower. By way of example, such instruments shall
not be amended to (i) increase the rate of interest with respect to the Subordinated Debt, or (ii) accelerate the payment of the principal or interest or any other portion of the Subordinated Debt. Bank shall have the sole and exclusive
right to restrict or permit, or approve or disapprove, the sale, transfer or other disposition of Collateral except in accordance with the terms of the Senior Debt. Upon written notice from Bank to Creditor of Bank’s agreement to release its
lien on all or any portion of the Collateral in connection with the sale, transfer or other disposition thereof by Bank (or by Borrower with consent of Bank), Creditor shall be deemed to have also, automatically and simultaneously, released its lien
on such Collateral, and Creditor shall upon written request by Bank, immediately take such action as shall be necessary or appropriate to evidence and confirm such release. All proceeds resulting from any such sale, transfer or other disposition
shall be applied first to the Senior Debt until payment in full thereof, with the balance, if any, to the Subordinated Debt, or to any other entitled party. If Creditor fails to release its lien as required hereunder, Creditor hereby appoints Bank
as attorney in fact for Creditor with full power of substitution to release Creditor’s liens as provided hereunder. Such power of attorney being coupled with an interest shall be irrevocable. 

If, at any time after payment in full of the Senior Debt any payments of the Senior Debt must be disgorged by Bank for any reason
(including, without limitation, the bankruptcy of Borrower), this Agreement and the relative rights and priorities set forth herein shall be reinstated as to all such disgorged payments as though such payments had not been made and Creditor shall
immediately pay over to Bank all payments received with respect to the Subordinated Debt to the extent that such payments would have been prohibited hereunder. At any time and from time to time, without notice to Creditor, Bank may take such actions
with respect to the Senior Debt as Bank, in its sole discretion, may deem appropriate, including, without limitation, terminating advances to Borrower, increasing the principal amount, extending the time of payment, increasing applicable interest
rates, renewing, compromising or otherwise amending the terms of any documents affecting the Senior Debt and any collateral securing the Senior Debt, and enforcing or failing to enforce any rights against Borrower or any other person. No such action
or inaction shall impair or otherwise affect Bank’s rights hereunder. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

2 

 This Agreement shall bind any successors or assignees of Creditor and shall benefit any
successors or assigns of Bank. This Agreement shall remain effective until terminated in writing by Bank. This Agreement is solely for the benefit of Creditor and Bank and not for the benefit of Borrower or any other party. Creditor further agrees
that if Borrower is in the process of refinancing any portion of the Senior Debt with a new lender, and if Bank makes a request of Creditor, Creditor shall agree to enter into a new subordination agreement with the new lender on substantially the
terms and conditions of this Agreement. 
 Creditor hereby agrees to execute such documents and/or take such further action as
Bank may at any time or times reasonably request in order to carry out the provisions and intent of this Agreement, including, without limitation, ratifications and confirmations of this Agreement from time to time hereafter, as and when requested
by Bank. 
 This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of
which together shall constitute one instrument. 
 This Agreement shall be governed by and construed in accordance with the laws
of the Commonwealth of Massachusetts, without giving effect to conflicts of laws principles. Creditor and Bank submit to the exclusive jurisdiction of the state and federal courts located in Boston, Massachusetts in any action, suit, or proceeding
of any kind, against it which arises out of or by reason of this Agreement; provided, however, that if for any reason Bank cannot avail itself of the Courts of The Commonwealth of Massachusetts, Creditor accepts jurisdiction of the Courts and venue
in Santa Clara County, California. CREDITOR AND BANK WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREIN. 

This Agreement represents the entire agreement with respect to the subject matter hereof, and supersedes all prior negotiations,
agreements and commitments. Creditor is not relying on any representations by Bank or Borrower in entering into this Agreement, and Creditor has kept and will continue to keep itself fully apprised of the financial and other condition of Borrower.
This Agreement may be amended only by written instrument signed by Creditor and Bank. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

3 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above written.

  

									
	 “Creditor”
	 	  	 	“Bank”
			
	 	 		 	 SILICON VALLEY BANK

					
	By:	 	  
	 		 	By:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

The undersigned approves of the terms of this Agreement. 
  

			
	 “Borrower”

	
	 BG MEDICINE, INC.

		
	 By:
	 	  

		
	 Title:
	 	  

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

4 

 EXHIBIT C 

EXHIBIT C 

21st
 March, 2008 Update 
 of Exhibit “A” attached to
that certain Intellectual Property Security Agreement dated November 9, 2007. 
 EXHIBIT “A” 

COPYRIGHTS 

SCHEDULE A - ISSUED COPYRIGHTS 

NO ISSUED COPYRIGHTS 

SCHEDULE B - PENDING COPYRIGHT APPLICATIONS 

NO PENDING COPYRIGHT APPLICATIONS 

SCHEDULE C - UNREGISTERED COPYRIGHTS (Where No Copyright Application is Pending) 

NO UNREGISTERED COPYRIGHTS 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

21st
 March, 2008 Update 
 of Exhibit “B” attached to that
certain Intellectual Property Security Agreement dated November 9, 2007. 
 EXHIBIT “B” 

PATENTS and PATENT APPLICATIONS 
  

											
	 PATENT

DESCRIPTION
	 	 DOCKET

No.
	 	 COUNTRY
	 	 SERIAL or

PATENT

No.
	 	 FILING DATE
	 	 STATUS

	 [***]
	 	[***]	 	 US
 US

International
 Europe

Switzerland
 Germany

France
 Great Britain

Japan
 Canada
	 	[***]	 	[***]	 	 Issued
 Issued

Expired
 Issued

Issued
 Issued

Issued
 Issued

Pending
 Pending

						
	 [***]
	 	[***]	 	 US Provisional
 US

US
 US

International
 Europe

Japan
 Australia

Canada
 Israel
	 	[***]	 	[***]	 	 Expired
 Pending

Pending
 Pending

Expired
 Pending

Pending
 Pending

Pending
 Pending

						
	 [***]
	 	[***]	 	 US Provisional
 US

International
 Europe

Japan
 Australia

Canada
 Hong Kong

Israel
 Singapore
	 	[***]	 	[***]	 	 Expired
 Pending

Expired
 Pending

Pending
 Pending

Pending
 Pending

Pending

Pending

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

Page 1 of 6 

											
	 [***]
	 	[***]	 	 US Provisional
 International

 US
 Europe

Australia
 Canada
	 	 [***]
	 	[***]	 	 Expired
 Expired

Revival
 Pending

Pending
 Pending

						
	 [***]
	 	[***]	 	 US Provisional
 International

 US
 Europe
	 	[***]	 	[***]	 	 Expired
 Expired

Pending
 in preparation

						
	 [***]
	 	[***]	 	 US Provisional
 International

	 	[***]	 	[***]	 	 Pending
 in
preparation

						
	 [***]
	 	[***]	 	 Europe
 PCT filing

US
 Canada

India
 Japan

Europe
	 	[***]	 	[***]	 	 Expired
 Expired

Pending
 Pending

Pending
 Pending

Allowed

						
	 [***]
	 	[***]	 	US	 	[***]	 	[***]	 	Pending
						
	 [***]
	 	[***]	 	 PCT
 US

Australia
 Canada

Europe
 Japan
	 	[***]	 	[***]	 	 Expired
 Pending

Pending
 Pending

Pending
 Pending

						
	 [***]
	 	[***]	 	US Provisional	 	[***]	 	[***]	 	Pending

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

Page 2 of 6 

											
	 [***]
	 	[***]	 	 Europe
 PCT

US
 Canada

Australia
 Japan

China
 India

Europe
 Hong Kong
	 	[***]	 	[***]	 	 Expired
 Expired

Pending
 Pending

Pending
 Pending

Pending
 Pending

Pending
 Pending

						
	 [***]
	 	[***]	 	US Provisional	 	[***]	 	[***]	 	Pending
						
	 [***]
	 	[***]	 	US Provisional	 	[***]	 	[***]	 	Pending
						
	 [***]
	 	[***]	 	 US Provisional
 US Provisional

	 	[***]	 	[***]	 	 Pending

Pending

						
	 [***]
	 	[***]	 	International	 	[***]	 	[***]	 	Pending

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

Page 3 of 6 

21st
 March, 2008 Update 
 of Exhibit “C” attached to
that certain Intellectual Property Security Agreement dated November 9, 2007. 
 EXHIBIT “C” 

TRADEMARKS and TRADEMARK APPLICATIONS 
  

											
	 TRADEMARK

DESCRIPTION
	 	 DOCKET No.
	 	 COUNTRY
	 	 SERIAL

No.
	 	 REGISTRATION

No.
	 	 STATUS

	 BEYOND GENOMICS
	 	BYG-601	 	Canada	 	1102891	 	TMA643,343	 	Allowed
	 BEYOND GENOMICS
	 	BYG-601	 	Europe	 	2213460	 	2213460	 	Registered
	 BEYOND GENOMICS
	 	BYG-601	 	Japan	 	2001-43940	 	4784213	 	Registered
	 BEYOND GENOMICS
	 	BYG-601	 	US	 	76/167,531	 	2737705	 	Registered
	 BEYOND GENOMICS
	 	BYG-601A	 	US	 	76/168,273	 	2722036	 	Registered
	 BG LOGO
	 	BYG-602	 	Canada	 	1102892	 	TMA645,183	 	Allowed
	 BG LOGO
	 	BYG-602	 	Europe	 	2213775	 	2213775	 	Registered
	 BG LOGO
	 	BYG-602	 	Japan	 	2001-43941	 	4784214	 	Registered
	 BG LOGO
	 	BYG-602	 	US	 	76/167,165	 	2719785	 	Registered
	 BG LOGO
	 	BYG-602A	 	US	 	76/167,700	 	2743152	 	Registered
	 BG LOGO &

BEYOND GENOMICS
	 	BYG-603	 	Europe	 	2213320	 	2213320	 	Registered
	 BG LOGO &

BEYOND GENOMICS
	 	BYG-603	 	Japan	 	2001-43942	 	4784215	 	Registered
	 BG LOGO &

BEYOND GENOMICS
	 	BYG-603	 	US	 	76/168,274	 	2722037	 	Registered
	 BG LOGO &

BEYOND GENOMICS
	 	BYG-603A	 	US	 	76/167,701	 	2722034	 	Registered
	 DIGITAL BIOLOGY
	 	BYG-604	 	US	 	76/167,535	 	2725092	 	Registered
	 DIGITAL BIOLOGY
	 	BYG-604A	 	US	 	76/171,976	 	2737721	 	Registered
	 BG MEDICINE
	 	BYG-605	 	US	 	77/165,708	 	3365104	 	Registered
	 BG MEDICINE
	 	BYG-605	 	Australia	 	1206593	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	Canada	 	*	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	China	 	*	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	Europe	 	*	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	India	 	*	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	Japan	 	2007-109374	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	Korea	 	2007-27994	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	Mexico	 	891,894	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	Norway	 	2007-13106	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	Russia	 	2007-733187	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	South Africa	 	*	 	—  	 	Pending
	 BG MEDICINE
	 	BYG-605	 	Switzerland	 	*	 	—  	 	Pending

  

	*	Awaiting Serial Numbers: National phases entered October 25/26, 2007 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

Page 4 of 6 

21st
 March, 2008 Update of 
 Exhibit “D” attached to
that certain Intellectual Property Security Agreement dated November 9, 2007. 
 EXHIBIT “D” 

MASK WORKS 

NO MASK WORKS 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

Page 5 of 6 

 EXHIBIT D 

 

	1.	The account referred to in 1(h)(2) is now held at SVB Asset Management. 

  

	2.	The tax appeal indicated in 7 has been paid. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

Page 6 of 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]